Inhibitor development in haemophilia A: The role of von Willebrand factor/factor VIII concentrates

Haemophilia

Volumn 13, Issue SUPPL. 5, 2007, Pages 47-51

  Goudemand, J ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Factor VIII concentrates; Haemophilia A; Inhibitors; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; EPITOPE; FANHDI; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; ENDOCYTOSIS; FAMILY HISTORY; GENETIC RISK; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 37149041623     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01571.x     Document Type: Article

References (39)

1. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26: 179-88.
2. Hay CR, Ludlam CA, Colvin BT et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-6.
3. Bray GL, Gomperts ED, Courter S et al. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83: 2428-35.
4. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
5. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: A case-control study. Br J Haematol 2005; 130: 422-7.
6. Goudemand J, Laurian Y, Calvez T. Risk of inhibitors in haemophilia and the type of factor replacement. Curr Opin Hematol 2006; 13: 316-22.
7. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study. Blood 2007; 109: 4648-54.
8. Chalmers EA, Brown SA, Keeling D et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-55.
9. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12(Suppl. 6): 15-22.
10. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-72.
11. Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-45.
12. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 5: 263-5.
13. Astermark J, Berntorp E, White GC, Kroner BL. The Malmo International Brother Study (MIBS): Further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001; 7: 267-72.
14. Lusher J, Abildgaard C, Arkin S et al. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: Final report on a hallmark clinical investigation. J Thromb Haemost 2004; 2: 574-83.
15. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
16. von Auer C, Oldenburg J, von Depka M et al. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates. Ann N Y Acad Sci 2005; 1051: 498-505.
17. Morado M, Villar A, Jimenez Yuste V, Quintana M, Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: Experience in one centre. Haemophilia 2005; 11: 79-83.
18. Gringeri A. Prospective controlled studies on prophylaxis: An Italian approach. Haemophilia 2003; 9(Suppl. 1): 38-42; discussion 43.
19. Guérois C, Laurian Y, Rothschild C et al. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost 1995; 73: 215-8.
20. Goudemand J. Incidence des inhibiteurs anti-FVIII chez des patients traités par Faceur VIII-LFB. STV 1998; 10: 77-81.
21. Rothschild C. Incidence des inhibiteurs chez les jeunes hémophiles A sévères, traités uniquement par facteurs VIII recombiants. STV 1998; 10: 82-5.
22. Rothschild C, Laurian Y, Satre EP et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: Incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998; 80: 779-83.
23. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
24. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgard U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: The CANAL cohort study. Blood 2007; 109: 4693-7.
25. Behrmann M, Pasi J, Saint-Remy JM, Kotitschke R, Kloft M. Von Willebrand factor modulates factor VIII immunogenicity: Comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-9.
26. Mannucci PM, Chediak J, Hanna W et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 2002; 99: 450-6.
27. Rodeghiero F. Introduction. Haematologica Rep 2005; 1: 1-2.
28. Federici AB. The factor VIII/von Willebrand factor complex: Basic and clinical issues. Haematologica 2003; 88: EREP02.
29. Lin Y, Yang X, Chevrier MC et al. Relationships between factor VIII:AG and factor VIII in recombinant and plasma-derived factor VIII concentrates. Haemophilia 2004; 10: 459-69.
30. Salvagno GL, Astermark J, Ekman M et al. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007; 13: 51-6.
31. Scandella D. New characteristics of anti-factor VIII inhibitor antibody epitopes and unusual immune responses to Factor VIII. Semin Thromb Hemost 2002; 28: 291-6.
32. Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand factor. Thromb Haemost 1998; 79: 456-65.
33. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88: EREP05.
34. Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia 2001; 7: 375-80.
35. Gensana M, Altisent C, Aznar JA et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia 2001; 7: 369-74.
36. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749-54.
37. Shima M, Nakai H, Scandella D et al. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Br J Haematol 1995; 91: 714-21.
38. Tagariello G, Zanotto D, Radossi P, Sartori R, Belvini D, Salviato R. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates. Am J Hematol 2007; 82: 460-2.
39. Dasgupta S, Repesse Y, Bayry J et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2.